AUPH
AUPH
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
5
$62.27M
Insider Sales
9
$6.70M
Total Volume
$68.97M
14 transactions
Net Activity
+$55.57M
Net buying
Sentiment Rating
Strong AccumulationCEO Conviction Index
High Conviction Accumulation
Key Drivers
- •Strong buying bias: purchases represent 90% of total transaction value.
- •CEO buying activity detected. When chief executives put their own money at risk, it is historically a strong bullish signal.
- •Ultra-high accumulation: total purchase value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Tang Kevin
CEO, 10%
$62.27M total
Greenleaf Peter
CEO
$2.87M total
Robertson Stephen P.
GC
$1.52M total
Donley Matthew Maxwell
COO
$994K total
Miller Joseph M
CFO
$940K total
Quick Actions
AUPH has an insider buy conviction of 90%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at AUPH (AUPH) engaged in a total of 14 transactions reported via SEC Form 4 filings. Among these, 5 were open-market purchases and 9 were sales. The total volume of insider trading reached $68.97M.
The net insider activity for AUPH shows a net buying bias of $55.57M. This activity represents a 90% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Purchase by Tang Kevin (Dir), who traded 1.30M shares valued at $13.59M on Aug 1, 2025.
Aurinia Pharmaceuticals Stock Price Forecast. Should You Buy AUPH?
Aurinia Pharmaceuticals (NASDAQ:AUPH) in Focus: Unusual Volume and the Latest Quarterly Report
Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?
AUPH - Aurinia Pharmaceuticals Inc Stock Price and Quote
Aurinia Pharmaceuticals (AUPH) Stock Price Slips After Q3 Earnings Strength
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million
FAQs About AUPH Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for AUPH.